Other Pharmaceuticals - LATAM

LATAM

Revenue in the Other Pharmaceuticals market is projected to reach US$17.83bn in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2028) of 3.79%, resulting in a market volume of US$20.69bn by 2028.
In global comparison, most revenue will be generated in the United States (US$260.50bn in 2024).

Key regions: China, Europe, Australia, United States, Germany

Market

Region

Region comparison

Currency

Analyst Opinion

The Pharmaceuticals market shows solid growth, which is mainly driven by innovative drugs and an increasing demand for healthcare, especially in emerging countries. Compared to the revenue generated by prescription drugs, OTC pharmaceuticals only play a minor role. The market for prescription drugs, for its part, is dominated by original products. This means that the larger number of OTC products, generics, and biosimilars sold cannot counterbalance the significantly higher prices of original products.

The commercially most successful drugs, the so-called "blockbusters," each generate more than US$1bn a year. Since single products can play a major role, certain markets are driven by only a small number of drugs. Some companies, in turn, generate a significant share of their revenue with only a handful of products.

The Pharmaceuticals market is characterized by disruptions due to innovative drugs and expiring patents. Research and development, which involves large costs as well as high risks and considerable uncertainties, is the main market driver. In general, the Pharmaceuticals market is highly regulated. It is usually characterized by strict approval processes and strong patent legislation. Regulations, the availability and approval of drugs, and the period of exclusivity vary greatly from country to country.

Oncology Drugs is by far the largest market market. In terms of regional share, the U.S. dominate the market, with Europe, Japan, and China also playing a significant role. The different markets have been affected very differently by the COVID-19 pandemic. While vaccines and antiviral drugs against the virus are generating additional revenue, and the development of mRNA drugs has received a boost, most pharmaceutical fields have been negatively impacted, mainly due to fewer new patients and barriers to healthcare access. After a shock in 2020, growth rates are back to pre-pandemic levels in most markets.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.